Satio Inc. Information

The SatioPatch™ Platform decentralizes care by Transforming Workflow for blood sampling, blood-based diagnostics, drug delivery and biometrics integration. Lab quality at home consumer-based diagnosis is enabled through a convenient and simple to use patch utilizing a wide variety of technologies to address an increasing demand for rapid, point of care diagnosis. This adhesive patch platform is being developed for drug and vaccine delivery with a reusable applicator and low-cost disposable with pressure sensors. The platform is designed to provide stable (through adhesive patch) and controlled (through motors) delivery to match the needs of a wide range of drugs and to improve the experience for chronic disease patients with recurring injections. Radical innovations in work flow include a remote tele-injection capability (video, biometrics, remote control, go/no-go sensors, EHR transmission) and a fully automated delivery through the intradermal or subcutaneous route of administration at Therapeutic Dose levels. The patch platform is also being developed for blood access and blood collection (wet and dry), on-board plasma separation, and 'sample-to-result' instrument-free, lab-free single use diagnostic devices. Satio, Inc. has been selected for multiple US Government Contracts. These include for ARPA-H (Advanced Research Projects Agency for Health) and BARDA (Biomedical Advanced Research and Development Authority). Products are not yet approved in US or other territories.